Welcoming you for any type of article submission for the upcoming issue on/before February 26, 2021.


Review Article
Volume 5 Issue 12 - 2020
A Misnomer, Polycystic Ovarian Syndrome, In Adult and Perimenopausal Women De Novo or Continuation from Adolescence!
Chhabra S*
Emeritus Professor, Obstetrics Gynecology, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Chief Executive Officer, Akanksha Shishugruha, Sevagram, Officer on Special Duty, Dr. Sushila Nayar Hospital, Utavali, Melghat Amravati, Kasturba Health Society, Sevagram, Wardha, Maharashtra, India
*Corresponding Author: Chhabra S, Emeritus Professor, Obstetrics Gynecology, Mahatma Gandhi Institute of Medical Sciences, Sevagram, Chief Executive Officer, Akanksha Shishugruha, Sevagram, Officer on Special Duty, Dr. Sushila Nayar Hospital, Utavali, Melghat Amravati, Kasturba Health Society, Sevagram, Wardha, Maharashtra, India.
Received: November 05, 2020; Published: December 11, 2020




Abstract

Introduction: There is scarce information about polycystic ovarian syndrome (PCOS) in adult, perimenopausal women. At this age symptoms are deceptive because of physiological changes at this age and due to multiorgan and multi system involvement. Overproduction of ovarian androgen, and Luteinizing hormone, are common. Clinical picture includes Menstrual irregularities, Sleep apnea, Obesity, Male pattern balding, Acanthosis negricans, Insulin resistance, Hyperinsulinemia. Polycystic ovaries may or may not be there. As age advances there is risk of hypertension, cardiovascular disease, diabetes mellitus, and endometrial carcinoma too.

Objective: Information about PCOS in adult, perimenopausal women.

Methodology: With available search engines studies, reviews were looked into. Opinions too were searched and self experiences added.

Results and Conclusion: It is being believed that PCOS of adolescence might persist or PCOS might occur de novo in perimenopausal women though some believe that it disappears around menopause. However, it is more difficult to diagnose, because at this age menstrual abnormalities and obesity are common. Etiology, pathology, genetic to insulin lipid metabolism are not very well known. Anti-Mullerian hormone might be responsible for some abnormalities. Fasting glucose insulin ratio and free testosterone are popular diagnostics, prevention has some limitations. Not much is known about efficacy of oral contraceptive pills in perimenopausal women though they are commonly used in adolescents and young women. Insulin-sensitizing agents can ameliorate IR, endocrinal, metabolic abnormalities. Metformin does lead to weight loss but dose not increase insulin secretion or hypoglycaemia. Attempts need to be made for prevention of obesity, diabetes. cardiovascular, disease, endometrial cancer. Long-term follow-up is essential.

Keywords: Polycystic Ovarian Syndrome; Adult, Premenopausal Women; Challenges

References

  1. Vassos N., et al. “Solid-pseudopapillary neoplasm (SPN) of the pancreas: case series and literature review on an enigmatic entity”. International Journal of Clinical and Experimental Pathology6 (2013): 1051.
  2. Kidson W. “Polycystic ovary syndrome: a new direction in treatment”. Medical Journal of Australia10 (1998): 537-540.
  3. Ovesen P., et al. “Normal basal and insulin-stimulated fuel metabolism in lean women with the polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism6 (1993): 1636-1640.
  4. Rotterdam EA-SPcwg. “Revised 2003 consensuss on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)”. Human Reproduction 19 (2003): 41-47.
  5. Taylor AE., et al. “Determinants of abnormal gonadtropin secretion in clinically defined women with polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 82 (1997): 2248-2256.
  6. Azziz R., et al. “Health care - realated economic burden of the polycystic ovary syndrome during the reproductive life span”. The Journal of Clinical Endocrinology and Metabolism 90 (2005): 4650-4658.
  7. Millerr K., et al. “Prevalence of polycystic ovary syndrome (PCOS)in first-degree relatives of patients with PCOS”. Fertility and Sterility 1 (2001): 53-58.
  8. Urbanek M., et al. “Thirty - seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistation”. Proceedings of the National Academy of Sciences of the United States of America 96 (1999): 8573-8578.
  9. Urbanek M. “The genetics of the polycystic ovary syndrome”. Nature Clinical Practice Endocrinology and Metabolism 2 (2007): 103-111.
  10. Dokras A., et al. “Screening women with polycystic ovary syndrome for metabolic syndrome”. Obstetrics and Gynecology1 (2005): 131-137.
  11. Franks S. “Diagnosis of polycystic ovarian syndrome: in defense of the Rotterdam criteria”. The Journal of Clinical Endocrinology and Metabolism3 (2006): 786-789.
  12. Kidson W. “Polycystic ovary syndrome. A new directin in treatment”. Medical Journal of Australia 169 (1998): 537-540.
  13. Coonn JJ., et al. “The prevalence of polycystic vaeies in women with type 2 diabetes mellitus”. Clinical Endocrinology 52 (2000): 81-86.
  14. Puurunen J., et al. “Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study”. The Journal of Clinical Endocrinology and Metabolism12 (2013): 4798-4807.
  15. Matsuda M and Defronzo RA. “Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp”. Diabetes Care 22 (1999): 1462-1470.
  16. Shaw LJ., et al. “Women and ischemic heart disease: evolving knowledge”. Journal of the American College of Cardiology17 (2009): 1561-1575.
  17. Puuruneen J., et al. “Adrenal androgen production capacity remains high uup tto menopause in women with polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 94 (2009): 1973-1978.
  18. Legro RS., et al. “Prevelence and predictors of risk for type 2 diabetes millitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women”. The Journal of Clinical Endocrinology and Metabolism 84 (1999):165-169.
  19. Carmina E and Lobo RA. “Do haperandrogenic women with normal menses have polycystic ovary syndrome?” Fertility and Sterility 71 (1999): 319-322.
  20. Azziz R., et al. “Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess society guideline”. The Journal of Clinical Endocrinology and Metabolism 91 (2006): 4237-4245.
  21. Goodarzi MO and Azziz R. “Diagnosis, epidemiologymy, and genetics of the polycystic ovary syndrome”. Best Practice and Research Clinical Endocrinology and Metabolism 20 (2006): 193-205.
  22. Talbott E., et al. “Adverse lipid and coronary heart risk profiles in young women with polycystic ovary syndrome: results of a case-control study”. Journal of Clinical Epidemiology 51 (1998): 415-422.
  23. Christiaan RC., et al. “Prevalence and predictors of coronary artery calcificaaation in women with polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 88 (2003): 2562-2568.
  24. Caro JF. “Leptin is normal in PCOS, an editorial about three “negative” papers”. The Journal of Clinical Endocrinology and Metabolism 82 (1997): 1685-1686.
  25. Fedoresak P., et al. “Obesity is a risk factor for early pregnancy loss after IVF or ICSI”. Acta Obstetricia et Gynecologica Scandinavica 79 (2000): 43-48.
  26. Spritzer PM., et al. “Leptin coneentration in hirsute women wwith polycystic ovary syndrome or idiopathie hirsutism: influence on LH and relationship with hormonal, metabolic, and anthropometric measurements”. Human Reproduction 16 (2001): 1340-1346.
  27. Ding EL., et al. “Sex hormone-binding globulin and risk of type 2 diabetes in women and men”. The New England Journal of Medicine 361 (2009): 1152-1163.
  28. EL-Gharib M and EL-Din hazaa S. “Salivary versus serum approaches in assessment of biochemical hyperandrogenemia”. Journal of Basic and Clinical Reproductive Sciences (2014): 54-57.
  29. Wild S., et al. “Cardiovascular disease in women with polycystic ovary syndrome at long-tem follow-up: a retrospective cohort study”. Clinical Endocrinology 52 (2000): 595-600.
  30. Johanna Puurunen., et al. “Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS”. JCEM (2011).
  31. Aspinall A. “Generation xxxl; Child obesity ‘timebomb’ waming with one girl aged 10 weighing 22st, Website (2013).
  32. Balen AH., et al. “Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients”. Human Reproduction 10 (1995): 2107-2111.
  33. Conway GS., et al. “Risk factors for coronary artery disease in lean and obese women with polycystic ovary syndrome”. Clinical Endocrinology 37 (1992): 119-125.
  34. Taponen S., et al. “Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort Study”. The Journal of Clinical Endocrinology and Metabolism (1966).
  35. Moran LJ., et al. “Impaired glucose tolerance, typs diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta -analysis”. Human Reproduction Update 16 (2010): 347-363.
  36. , et al. “Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 90.4 (2013): 1929-1935.
  37. , et al. “Precalence and characteristixs of the metabolic syndrome in polcystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 90 (2005): 1929-1935.
  38. Legro RS., et al. “Prevalence and predictors of dysslipidemia in women with polycystic ovary syndrome”. The American Journal of Medicine 117 (2001): 607-606.
  39. Swanson M., et al. “Medical implication of ultrasonically detected polycystic ovaries”. The Journal of Clinical Ultrasound 9 (1981): 219-222.
  40. Fox R. “Transvaginal ultrasound appearances of the ovary in normal women and hirsute women with oligomenorrhoea”. The Australian and New Zealand Journal of Obstetrics and Gynaecology 39 (1999): 63-68.
  41. Shayya R and Chang RJ. “Reporductive endocrinology of adolescent polycystic ovary syndrome”. British Journal of Obstetrics and Gynaecology 117 (2010): 150-155.
  42. Nagamani M., et al. “Increased bioactive liteinizing hormone levels and bio/immune ratio in women with hyperthecosis of the ovaries: possible role of hyperinsulinmia”. The Journal of Clinical Endocrinology and Metabolism 84 (1999): 679-688.
  43. Douglas CC., et al. “Role of diet in the treatment of polycystic ovary syndrome”. Fertility and Sterility 85 (2006): 679-688.
  44. Pawelczyk L., et al. “Metformin therapy increases insulin-like growth factor bonding protein-1 in hyperinsulinemic womrn with polycystic ovary syndrome”. European Journal of Obstetrics & Gynecology and Reproductive Biology 113 (2004): 209-213.
  45. Wulffele MG., et al. “The effect of metformin on bblood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review”. Journal of Internal Medicine 256 (2004): 14.
  46. Yan B., et al. “Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta‐analysis”. Clinical Endocrinology3 (2011): 332-339.
  47. Papunen LC., et al. “Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study”. The Journal of Clinical Endocrinology and Metabolism 85 (2000): 3161-3168.
  48. Harwood K., et al. “Current approaches to the diagnosis aand treatment of polycystic ovarian syndrome in youth”. Hormone Research in Paediatrics 68 (2007): 209-217.
  49. Rouru J., et al. “Serum leptin concentrations in women with polycystic ovary syndrome”. The Journal of Clinical Endocrinology and Metabolism 6 (1997): 1697-1700.
  50. Eagleson CA., et al. “Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone”. The Journal of Clinical Endocrinology and Metabolism 11 (2000): 4047-4052.
  51. Walska l., et al. “Insulin, leptin, IGF-I and insulin-dependent protein concentration after insulin-sensitizing therapy in obese women with polycystic ovary syndrome”. European Journal of Endocrinology 144 (2001): 509-515.
  52. Insler V., et al. “The effect of different LH-RH agonists on the levels of immunoreactive gonadotropins”. Gynecological endocrinology: the official journal of the International Society of Gynecological Endocrinology 4 (1988): 305.
Citation: Chhabra S. “A Misnomer, Polycystic Ovarian Syndrome, In Adult and Perimenopausal Women De Novo or Continuation from Adolescence!”. EC Endocrinology and Metabolic Research 6.1 (2021): 01-09.

PubMed Indexed Article


EC Pharmacology and Toxicology
LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.

PMID: 31143884 [PubMed]

PMCID: PMC6536005


EC Pharmacology and Toxicology
Alzheimer's Pathogenesis, Metal-Mediated Redox Stress, and Potential Nanotheranostics.

PMID: 31565701 [PubMed]

PMCID: PMC6764777


EC Neurology
Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study.

PMID: 27747317 [PubMed]

PMCID: PMC5065347


EC Pharmacology and Toxicology
Will Blockchain Technology Transform Healthcare and Biomedical Sciences?

PMID: 31460519 [PubMed]

PMCID: PMC6711478


EC Pharmacology and Toxicology
Is it a Prime Time for AI-powered Virtual Drug Screening?

PMID: 30215059 [PubMed]

PMCID: PMC6133253


EC Psychology and Psychiatry
Analysis of Evidence for the Combination of Pro-dopamine Regulator (KB220PAM) and Naltrexone to Prevent Opioid Use Disorder Relapse.

PMID: 30417173 [PubMed]

PMCID: PMC6226033


EC Anaesthesia
Arrest Under Anesthesia - What was the Culprit? A Case Report.

PMID: 30264037 [PubMed]

PMCID: PMC6155992


EC Orthopaedics
Distraction Implantation. A New Technique in Total Joint Arthroplasty and Direct Skeletal Attachment.

PMID: 30198026 [PubMed]

PMCID: PMC6124505


EC Pulmonology and Respiratory Medicine
Prevalence and factors associated with self-reported chronic obstructive pulmonary disease among adults aged 40-79: the National Health and Nutrition Examination Survey (NHANES) 2007-2012.

PMID: 30294723 [PubMed]

PMCID: PMC6169793


EC Dental Science
Important Dental Fiber-Reinforced Composite Molding Compound Breakthroughs

PMID: 29285526 [PubMed]

PMCID: PMC5743211


EC Microbiology
Prevalence of Intestinal Parasites Among HIV Infected and HIV Uninfected Patients Treated at the 1o De Maio Health Centre in Maputo, Mozambique

PMID: 29911204 [PubMed]

PMCID: PMC5999047


EC Microbiology
Macrophages and the Viral Dissemination Super Highway

PMID: 26949751 [PubMed]

PMCID: PMC4774560


EC Microbiology
The Microbiome, Antibiotics, and Health of the Pediatric Population.

PMID: 27390782 [PubMed]

PMCID: PMC4933318


EC Microbiology
Reactive Oxygen Species in HIV Infection

PMID: 28580453 [PubMed]

PMCID: PMC5450819


EC Microbiology
A Review of the CD4 T Cell Contribution to Lung Infection, Inflammation and Repair with a Focus on Wheeze and Asthma in the Pediatric Population

PMID: 26280024 [PubMed]

PMCID: PMC4533840


EC Neurology
Identifying Key Symptoms Differentiating Myalgic Encephalomyelitis and Chronic Fatigue Syndrome from Multiple Sclerosis

PMID: 28066845 [PubMed]

PMCID: PMC5214344


EC Pharmacology and Toxicology
Paradigm Shift is the Normal State of Pharmacology

PMID: 28936490 [PubMed]

PMCID: PMC5604476


EC Neurology
Examining those Meeting IOM Criteria Versus IOM Plus Fibromyalgia

PMID: 28713879 [PubMed]

PMCID: PMC5510658


EC Neurology
Unilateral Frontosphenoid Craniosynostosis: Case Report and a Review of the Literature

PMID: 28133641 [PubMed]

PMCID: PMC5267489


EC Ophthalmology
OCT-Angiography for Non-Invasive Monitoring of Neuronal and Vascular Structure in Mouse Retina: Implication for Characterization of Retinal Neurovascular Coupling

PMID: 29333536 [PubMed]

PMCID: PMC5766278


EC Neurology
Longer Duration of Downslope Treadmill Walking Induces Depression of H-Reflexes Measured during Standing and Walking.

PMID: 31032493 [PubMed]

PMCID: PMC6483108


EC Microbiology
Onchocerciasis in Mozambique: An Unknown Condition for Health Professionals.

PMID: 30957099 [PubMed]

PMCID: PMC6448571


EC Nutrition
Food Insecurity among Households with and without Podoconiosis in East and West Gojjam, Ethiopia.

PMID: 30101228 [PubMed]

PMCID: PMC6086333


EC Ophthalmology
REVIEW. +2 to +3 D. Reading Glasses to Prevent Myopia.

PMID: 31080964 [PubMed]

PMCID: PMC6508883


EC Gynaecology
Biomechanical Mapping of the Female Pelvic Floor: Uterine Prolapse Versus Normal Conditions.

PMID: 31093608 [PubMed]

PMCID: PMC6513001


EC Dental Science
Fiber-Reinforced Composites: A Breakthrough in Practical Clinical Applications with Advanced Wear Resistance for Dental Materials.

PMID: 31552397 [PubMed]

PMCID: PMC6758937


EC Microbiology
Neurocysticercosis in Child Bearing Women: An Overlooked Condition in Mozambique and a Potentially Missed Diagnosis in Women Presenting with Eclampsia.

PMID: 31681909 [PubMed]

PMCID: PMC6824723


EC Microbiology
Molecular Detection of Leptospira spp. in Rodents Trapped in the Mozambique Island City, Nampula Province, Mozambique.

PMID: 31681910 [PubMed]

PMCID: PMC6824726


EC Neurology
Endoplasmic Reticulum-Mitochondrial Cross-Talk in Neurodegenerative and Eye Diseases.

PMID: 31528859 [PubMed]

PMCID: PMC6746603


EC Psychology and Psychiatry
Can Chronic Consumption of Caffeine by Increasing D2/D3 Receptors Offer Benefit to Carriers of the DRD2 A1 Allele in Cocaine Abuse?

PMID: 31276119 [PubMed]

PMCID: PMC6604646


EC Anaesthesia
Real Time Locating Systems and sustainability of Perioperative Efficiency of Anesthesiologists.

PMID: 31406965 [PubMed]

PMCID: PMC6690616


EC Pharmacology and Toxicology
A Pilot STEM Curriculum Designed to Teach High School Students Concepts in Biochemical Engineering and Pharmacology.

PMID: 31517314 [PubMed]

PMCID: PMC6741290


EC Pharmacology and Toxicology
Toxic Mechanisms Underlying Motor Activity Changes Induced by a Mixture of Lead, Arsenic and Manganese.

PMID: 31633124 [PubMed]

PMCID: PMC6800226


EC Neurology
Research Volunteers' Attitudes Toward Chronic Fatigue Syndrome and Myalgic Encephalomyelitis.

PMID: 29662969 [PubMed]

PMCID: PMC5898812


EC Pharmacology and Toxicology
Hyperbaric Oxygen Therapy for Alzheimer's Disease.

PMID: 30215058 [PubMed]

PMCID: PMC6133268


News and Events


April Issue Release

We always feel pleasure to share our updates with you all. Here, notifying you that we have successfully released the April issue of respective journals and the latest articles can be viewed on the current issue pages.

Submission Deadline for upcoming Issue

Ecronicon delightfully welcomes all the authors around the globe for effective collaboration with an article submission for the upcoming issue of respective journals. Submissions are accepted on/before April 26, 2021.

Certificate of Publication

Ecronicon honors with a "Publication Certificate" to the corresponding author by including the names of co-authors as a token of appreciation for publishing the work with our respective journals.

Best Article of the Issue

Editors of respective journals will always be very much interested in electing one Best Article after each issue release. The authors of the selected article will be honored with a "Best Article of the Issue" certificate.

Certifying for Review

Ecronicon certifies the Editors for their first review done towards the assigned article of the respective journals.

Latest Articles

The latest articles will be updated immediately on the articles in press page of the respective journals.

Immediate Assistance

The prime motto of this team is to clarify all the queries without any delay or hesitation to avoid the inconvenience. For immediate assistance on your queries please don't hesitate to drop an email to editor@ecronicon.uk